OTCM
SKVI
Market cap1mUSD
Oct 05, Last price
0.20USD
1D
0.25%
1Q
-7.91%
Jan 2017
1,166.25%
Name
Skinvisible Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Skinvisible, Inc., together with its associated entities, specializes in the creation, production, and distribution of advanced polymer-based delivery system technologies. These proprietary systems facilitate the topical, transdermal, and mucosal application of active ingredients, serving various sectors including pharmaceuticals (both prescription and over-the-counter), personal skincare, and cosmetics. Beyond dermatological applications, the company's non-dermatological formulations address specific needs in women's health, pain management, and other diverse markets. Under the 'Skinbrella' brand, Skinvisible provides consumer products such as sunless tanning lotions and sunscreens. Their business model also encompasses licensing these technologies to pharmaceutical and consumer goods companies. Furthermore, they assist pharmaceutical clients with early-stage formulation development. A key service involves reformulating existing pharmaceutical products nearing patent expiration, utilizing their unique Invisicare patent to introduce new product benefits and facilitate line extensions. Incorporated in 1998, the company originally operated as Microbial Solutions, Inc. before adopting the name Skinvisible, Inc. in February 1999. It maintains its headquarters in Las Vegas, Nevada.
Key people
Terry Howlett
Chief Executive Officer, Chief Financial Officer, Director · since 1998
Doreen Mcmorran
Vice President - Business Development
Independent Director · since 2017
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||